Fexofast

Quick links to important sections

Fexofast

Selected form

Treatment option: Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fexofast

Quick Facts

Property Description
Active ingredient Fexofenadine hydrochloride
Form Tablet, film-coated tablet, oral suspension
Pharmacological class Selective peripheral H1-receptor antagonist
Common use General relief of allergy symptoms
Origin Synthetic compound, active metabolite of terfenadine

What Type of Medicine is Fexofast?

Fexofast is a medication containing the active ingredient, Fexofenadine hydrochloride, which is classified as a second-generation antihistamine and a selective peripheral H1-receptor antagonist. The active compound functions by blocking the action of histamine, a substance in the body that naturally triggers allergic symptoms.

This drug is a synthetic piperidine derivative and is significant because it functions as the major active metabolite of the older compound, terfenadine. This intentional chemical design retained anti-allergic efficacy while eliminating the cardiovascular safety concerns associated with its precursor. Its inclusion on the World Health Organization’s List of Essential Medicines further supports its established therapeutic value and clinical recognition.

Composition and Physical Forms

The composition of Fexofast features Fexofenadine hydrochloride as the sole therapeutic agent, making it a single-ingredient anti-allergic product delivered via the oral administration route. The medication is available in multiple high-level dosage forms, including the standard film-coated tablet and the oral suspension. The liquid suspension form offers a viable alternative for patient groups, such as pediatric individuals, who may have difficulty swallowing solid medication.

What is the General Purpose of Fexofenadine?

The general purpose of Fexofenadine is to provide relief from the physical manifestations of allergies by preventing histamine from engaging peripheral receptors. This includes scenarios where an individual requires relief from common allergic reactions without impaired cognitive function.

Its most critical differentiating property is its designation as a non-sedating compound. This status is characterized by its minimal ability to cross the blood-brain barrier, allowing it to target allergic symptoms in the body's periphery without inducing the noticeable drowsiness typical of older antihistamines.

Regulatory References

  1. Fexofenadine: MedlinePlus Drug Information (NIH)
  2. Fexofenadine on WHO Essential Medicines List
  3. Fexofenadine: DrugBank Online

What side effects are possible with Fexofast?

Possible Side Effects and Safety Information

This section describes the adverse reactions and high-level safety characteristics of Fexofast (Fexofenadine hydrochloride) as documented in official government regulatory information.


Frequency-Classified Adverse Reactions

Side effects are categorized by the frequency observed in controlled clinical trials for adults and adolescents (ge 12 years). The most frequently documented reactions are classified as Common.

System-Organ Class Common Adverse Reactions (Adults) Frequency Not Known (Post-Marketing)
Nervous System Headache, Dizziness, Drowsiness Insomnia, Nervousness, Sleep Disorders
Gastrointestinal Nausea, Stomach discomfort Diarrhea
General Disorders Fatigue -
Cardiac - Tachycardia, Palpitations
Immune System - Hypersensitivity Reactions

Serious adverse reactions, reported rarely during post-marketing surveillance and thus classified as Frequency Not Known, include severe systemic allergic responses such as systemic anaphylaxis, angioedema (swelling), dyspnea (shortness of breath), and chest tightness.


Population-Specific Safety Considerations

Specific attention is paid to how the medicine is processed in certain patient groups. Individuals with renal impairment may experience a prolonged half-life and higher peak plasma levels of fexofenadine, which is a noted safety consideration in official labeling. Older adults may also exhibit increased sensitivity to the effects of the medication. The profile of common side effects differs in pediatric populations; for example, children aged 6 to 11 may more frequently report cough and otitis media, while younger children may more frequently report vomiting and somnolence.

Safety-Related Restrictions

Fexofast is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients. Regulatory documents also note that co-administration with aluminum- or magnesium-containing antacids and certain fruit juices (such as grapefruit, orange, or apple) can reduce the systemic exposure of fexofenadine.

Overdose and Emergency Response

Overdose and When to Seek Help

If you take too much Fexofast (fexofenadine), contact your doctor or the nearest hospital emergency department immediately. You should also get medical help or contact a Poison Control Center right away in case of an overdose.

Documented Overdose Symptoms

Symptoms that have been reported in cases of fexofenadine overdose include:

  • Dizziness
  • Drowsiness
  • Fatigue
  • Dry mouth

Although reports of fexofenadine overdose are infrequent and contain limited clinical information, regulatory documents note that in clinical trials, healthy volunteers tolerated high single doses (up to 800, mg) and high chronic doses without clinically significant adverse effects compared to placebo.

Required Emergency Actions

In the event of an overdose, the recommended management is symptomatic and supportive treatment. Healthcare professionals should also consider standard measures to remove any unabsorbed drug from the system. It is important to note that hemodialysis has been shown to not be an effective measure for removing fexofenadine from the blood, with only a minimal amount (approximately 1.7%) removed.

Therapeutic Uses of Fexofast

What Fexofast Treats: Main Uses and Benefits

Fexofast is generally applied in contexts where supportive symptom management is appropriate for allergic reactions. The medication helps with supportive symptomatic relief for the two main therapeutic indications. It is considered relevant in conditions involving episodic or fluctuating manifestations, such as seasonal allergic rhinitis (hay fever), and recurrent symptomatic discomfort, like chronic idiopathic urticaria (hives).


Symptom Relief and Patient Benefit

Common clinical scenarios involve assisting with symptom clusters such as sneezing, runny or itchy nose, itchy throat, and watery or red eyes. The medication is applied when symptoms create noticeable functional strain, which makes it relevant when short-term symptomatic assistance is needed. This supportive relief may help improve day-to-day comfort and assists with maintaining functional stability during symptomatic periods. For managing skin symptoms, it is applied when additional management of discomfort is required, focusing on reducing the persistent itching (pruritus) and the accompanying rash.


Quick Fact: Symptomatic Support for Allergic Discomfort

Fexofast assists with managing symptoms related to physical discomfort across both seasonal allergy episodes and conditions presenting with systemic or localized discomfort, like chronic hives. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Use of Fexofast is strictly governed by officially documented population eligibility rules.

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to fexofenadine or any of the product's ingredients.
Age-related eligibility rules Approved for adults and adolescents ge 12 years (tablets/capsules). Approved for children 6 months to 11 years (oral suspension) for specific conditions. Safety and efficacy not established in children under 6 months.
Pregnancy and lactation eligibility status Not recommended during pregnancy unless clearly necessary. Not recommended for mothers who are breastfeeding.
Eligibility-related restrictions Patients with decreased renal function are eligible but require a restricted starting dose as specified by the regulatory label. Use with caution is advised for older adults due to the higher likelihood of age-related kidney problems.

Connection to the Overall Eligibility Profile

The eligibility profile establishes the absolute contraindication based on known hypersensitivity. The primary restriction is age-group approval, which dictates the appropriate product formulation (tablet vs. suspension). Conditional use is defined by physiological status, specifically requiring caution or a dose restriction in patients with impaired kidney function as documented in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fexofast (fexofenadine) has a known interaction profile that is defined primarily by pharmacokinetic modifications altering the amount of medicine available in the body. Unlike many other medicines, Fexofenadine undergoes minimal hepatic metabolism, meaning it has a low potential for interactions mediated by the CYP enzyme system.


Documented Pharmacokinetic Interactions

The most significant documented drug-drug interactions are attributed to transport-related effects, specifically the inhibition of efflux and uptake transporters, rather than metabolic enzymes.

Interacting Substance Official Effect on Fexofast Exposure Restriction/Condition
Erythromycin (Antibacterial) Substantially increases systemic exposure (AUC and Cmax). Use with caution due to increased exposure.
Ketoconazole (Antifungal) Substantially increases systemic exposure (AUC and Cmax). Use with caution due to increased exposure.

Administration Timing and Absorption Constraints

Certain substances interfere directly with the absorption of Fexofast in the digestive tract, requiring mandatory separation of administration time.

  • Aluminum and Magnesium-Containing Antacids: These preparations significantly decrease Fexofenadine absorption, leading to reduced systemic exposure. A mandatory separation of at least two hours between Fexofast and antacid administration is required by regulatory documents.
  • Fruit Juices: The co-ingestion of Fexofast with grapefruit, orange, and apple juices is officially documented to reduce the medicine's bioavailability and systemic exposure.

In populations with decreased renal function, there is a greater risk of increased systemic exposure of Fexofenadine due to the body's altered ability to clear the medicine.

Mechanism of Action

How Fexofast works


Targeted H1-Receptor Antagonism

The core mechanism of Fexofast involves acting as an antagonist on Histamine H1-receptors located on various cell surfaces, primarily in peripheral tissues. This molecular interaction physically prevents the natural chemical messenger, histamine, from binding to these receptors. By occupying the H1-receptor binding site, the drug halts the subsequent intracellular signaling cascade that would normally be initiated by histamine. This blockade modifies the early molecular steps that influence vascular activity and other physiological responses regulated by H1-receptor activation.

Selective Peripheral Modulation

The chemical properties of Fexofast limit its ability to permeate the blood-brain barrier. This selectivity ensures that its action is focused predominantly on peripheral systems outside the central nervous system. This targeted activity alters key physiological functions mediated by peripheral H1-receptors, specifically influencing vascular permeability (fluid leakage from capillaries) and smooth muscle tone. This mechanism results in an altered signaling pattern within these pathways, due to its limited interaction with H1-receptors in the central nervous system.

Dosage and Administration Information

How to Use Fexofast

Fexofast (Fexofenadine hydrochloride) is a second-generation antihistamine indicated for the symptomatic management of allergic conditions. The instructions below describe the standardized administration and dosing established for this medication.


Official Administration and Dosage

Usage Aspect Administration Guideline
Route of Administration Oral intake only, available as a film-coated tablet or oral suspension.
Dosing Frequency Typically once daily (OD) for standard adult regimens.
Standard Adult Dose 180 mg once daily for Chronic Idiopathic Urticaria (Hives) or 120 mg once daily for Seasonal Allergic Rhinitis (Hay Fever).
Use Pattern May be used episodically (as needed during symptomatic periods) or continuously (for chronic conditions).

Administration Conditions and Adjustments

For proper use, Fexofast should be taken with water. Standard instructions emphasize that the medicine must not be taken with fruit juices (such as grapefruit, orange, or apple juice), as these beverages can significantly interfere with the drug's absorption, reducing its effectiveness.

Population-Specific Rules: Dosing adjustments are required for certain groups. For patients with renal impairment, a reduced adult dose (e.g., 60 mg once daily) is typically specified. Pediatric patients require age- or weight-appropriate dosing, such as 30 mg twice daily for children aged 6 to 11 years, often utilizing the oral suspension form.

In the event of a missed dose, the next dose should be taken at the regularly scheduled time; a double dose must not be taken to compensate.

Recent Clinical Evidence

Fexofast: Recent Clinical Evidence


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The research exploring Fexofast in relation to common symptoms related to seasonal allergic rhinitis (hay fever) has primarily used high-quality designs, including randomized controlled trials (RCTs). These short-term studies are used in research exploring how symptoms change over time. The available evidence also includes meta-analyses, which compile the findings from multiple trials to examine overall patterns. Studies also explored outcomes reflecting daily functioning, such as the measured impact on health-related Quality of Life (QoL) and daily activities. What remains uncertain is the full picture of outcomes linked to long-term use. Available clinical evidence is characterized by a reliance on short-term follow-up periods, often just 14 to 15 days. Long-term effects are not fully established.


Evidence for Use in Chronic Idiopathic Urticaria (CIU)

For chronic idiopathic urticaria (CIU), or chronic hives, the research base is also primarily composed of short-term randomized controlled trials (RCTs) that compare Fexofast against a placebo. These studies focus on conditions characterized by fluctuating or episodic manifestations and monitor symptoms over defined time intervals. Research examined outcomes related to systemic or functional imbalance by monitoring specific symptoms over the study duration. Studies monitored outcomes describing perceived discomfort, such as the change in the severity of pruritus (itching) and the reduction in the number of wheals (hives/rash) across the body. Research on extended symptom patterns over extended periods is not fully established, as the key efficacy trials have short treatment durations, typically four to six weeks.


Study Focus on Special Populations and Gaps

Research for allergic rhinitis included subjects from the adult and adolescent populations. Pediatric groups, specifically children between the ages of 6 and 11 years, were also observed in trials assessing short-term symptom patterns. For all indications, research mainly describes results that apply only to the populations studied in the RCTs. Data for certain groups remain insufficient, such as very older adults or patients with specific, complex comorbidities. The key evidence gaps relate primarily to the duration and scope of the studies. The certainty remains low for outcomes in some subgroups because the sample sizes were modest or the data for certain groups remain insufficient.

Key Studies & References

  1. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

Frequently Asked Questions (FAQ)

Common questions about Fexofast (FAQ)


Q: Is Fexofast safe to use long-term for chronic allergies?

A: Official studies on Fexofast have primarily focused on short-term use, such as periods of two to four weeks. While some evidence indicates no tolerance develops over these short timeframes, the safety and efficacy of continuous use over extended periods are not fully established in official regulatory documents.

Q: Can people with kidney or liver problems use Fexofast?

A: Official regulatory information indicates that individuals with decreased renal function (kidney problems) may need a dosage adjustment because the medicine is cleared more slowly by the body. However, regulatory documents do not provide specific dose adjustments or safety information regarding isolated liver problems.

Q: What is the safety profile of Fexofast for older adults?

A: Official warnings note that caution is advised when Fexofast is used by older adults, as they may exhibit increased sensitivity to the effects of the medicine. Furthermore, a reduced dose may be appropriate for older patients who have decreased kidney function, which can affect how the drug is processed.

Q: Can children of all ages use Fexofast?

A: Official regulatory documents establish specific age limits for the use of Fexofast. The safety and efficacy of the medicine are not established for children under six months of age for any condition. The approved forms and doses vary significantly based on the specific age group.

Q: What is the main difference between Fexofast and other common allergy pills?

A: Official documents classify Fexofast as a selective peripheral H1-receptor antagonist, meaning it primarily targets receptors outside the brain and spinal cord. This specific mechanism means it has minimal ability to cross the blood-brain barrier, which is why it is officially designated as a non-sedating second-generation antihistamine.

Q: How quickly should I expect Fexofast to start working after I take it?

A: Official pharmacological studies indicate that an antihistamine effect can be measured in the body starting within one hour after a single dose is taken. The maximum therapeutic effect of the medicine is generally reached within two to three hours after administration.

Q: What is the expected duration of Fexofast's effect?

A: Fexofast is classified as a long-acting medicine. Official pharmacokinetic data indicates that the mean elimination half-life of the active ingredient is approximately 14.4 hours in healthy volunteers.

Q: Can Fexofast be taken with food, or does it need to be taken on an empty stomach?

A: Official administration instructions emphasize taking Fexofast with plain water and strictly warn against taking it with fruit juices, which can reduce its absorption. For single-ingredient tablets, the label does not explicitly mandate an empty stomach, but administration instructions for some combination products containing Fexofast specify taking them without food.

Q: Can Fexofast affect my ability to drive or operate machinery?

A: Official regulatory sections state that Fexofenadine is generally unlikely to affect a person’s ability to drive or operate machinery. However, due to the possibility of side effects like dizziness or drowsiness, regulatory guidance recommends that individuals assess their own reaction to the medicine before operating machinery or driving.

Q: Is Fexofast an over-the-counter (OTC) medicine, or is it prescription only?

A: Fexofast is widely available in many regions as an over-the-counter (OTC) medicine in specific approved formulations for adults and children. However, official status can vary by country, and some specific higher strengths or combination products may still require a prescription.

Q: Does Fexofast treat nasal congestion, or just the sneezing and itching?

A: As a single-ingredient product, Fexofast is indicated for common allergy symptoms, including sneezing, runny nose, and itching. Relief for nasal congestion is provided by separate combination products that incorporate a decongestant ingredient.

Q: Is it possible for Fexofast to stop working after I've used it for a long time?

A: Official clinical studies that observed patients over a period of up to 28 days showed no evidence of tolerance developing to the antihistamine effects of Fexofast. This indicates that the medicine is expected to continue working consistently during short-term, continuous use.

Q: Is there a generic version of Fexofast available?

A: Yes, the active ingredient in Fexofast, which is fexofenadine hydrochloride, has been officially confirmed by regulatory bodies to be available in generic formulations.

Q: Can Fexofast interact with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory documents focus on significant interactions that affect how Fexofast is absorbed or transported in the body, such as with certain antibiotics and antifungals. Specific interaction data for common non-prescription pain relievers like ibuprofen or acetaminophen are not listed as a major documented drug-drug interaction.

Q: What evidence or research supports the use of Fexofast for its approved indications?

A: The approved uses for Fexofast, including Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria, are supported by findings from randomized, controlled clinical trials (RCTs). These studies demonstrated that the medicine is effective in reducing symptoms compared to a placebo.

Q: Does Fexofast have any known interactions with herbal supplements?

A: Official drug labels for Fexofast do not currently list any specific interactions with particular herbal supplements. General regulatory guidance recommends caution when combining any medicine with herbal products, as these products may not have been fully studied for interaction potential.

Q: Can Fexofast be taken at the same time as cold and flu medications?

A: While this specific combination is not strictly forbidden in all regulatory labels, official guidance recommends consulting a health professional before combining Fexofast with other cold or flu medications. This is especially important if those other products contain ingredients like decongestants, which could have potential additive effects.

Q: Does Fexofast cause weight gain?

A: Based on the primary clinical trial data submitted to regulatory agencies, weight gain is not listed as one of the common or frequently reported adverse reactions associated with Fexofast.

Q: What are the official warnings about Fexofast and alcohol consumption?

A: Official regulatory labeling for Fexofast typically does not include a specific contraindication or blanket warning against consuming alcohol. This is often because clinical studies have indicated that Fexofenadine does not significantly increase the effects of alcohol on performance, unlike older, sedating antihistamines.

Q: Can Fexofast interact with vitamins or mineral supplements?

A: The most significant interaction involving minerals is with magnesium- and aluminum-containing antacids, which must be separated by two hours to prevent reduced absorption. Other general vitamin or mineral supplements are not specifically listed as known interacting substances in core regulatory documents.

Q: Why are there different dosages available for Fexofast?

A: Official documents specify different available dosages to account for several factors in the patient population. These factors include the condition being treated (such as hay fever versus chronic hives), the patient's age group (adults versus children), and any known decrease in kidney function.

Q: What are the main differences between the various available strengths of Fexofast?

A: The various strengths of Fexofast are designed to align with the recommended dose for a specific condition or patient group. Official dosing guidelines specify the appropriate strength to be used depending on the patient's condition and specific eligibility criteria.

Q: Does Fexofast cause dry mouth or dry eyes?

A: While dry mouth may not be listed among the most common adverse reactions in all clinical trials, some official post-marketing surveillance reports list dry mouth as a possible undesirable effect. It is important to note that the profile of reported side effects can differ depending on the population studied.

Q: Is Fexofast effective for year-round indoor allergies?

A: Yes, Fexofast is officially indicated for the symptomatic relief of both Seasonal Allergic Rhinitis (SAR, or hay fever) and Perennial Allergic Rhinitis (PAR). This means the medicine is approved to help manage allergy symptoms that occur year-round, including those related to indoor triggers.

Q: What is the general expectation for relief when using Fexofast for hay fever?

A: Official clinical trials for hay fever showed that patients experienced a measurable reduction in allergy symptoms following their first dose. The effect is generally expected to be maintained over a 12-hour or 24-hour period, depending on the specific approved dosing regimen.

Q: What is the official classification of Fexofast regarding its potential for abuse or dependence?

A: Fexofast is officially classified as a non-controlled substance by regulatory agencies. It is not scheduled under the Controlled Substances Act, meaning that based on official assessment, the medicine has no established potential for abuse or dependence.

Q: Does taking more Fexofast make it work faster or better?

A: Regulatory instructions limit the amount that may be taken and state that a double dose must not be used to compensate for any reason. Taking more than the recommended amount does not increase the intended therapeutic benefit and may instead increase the risk of side effects like dizziness and drowsiness.

Q: Is it necessary to consult a healthcare provider before starting Fexofast?

A: Because Fexofast is available in approved over-the-counter (OTC) formulations, a prescription or initial consultation is not strictly required for purchase when used according to the label. However, official guidance recommends consulting a health professional if a person has pre-existing medical conditions, such as kidney problems, or if they are taking other medicines.

Q: Does Fexofast contain any decongestants?

A: As a single-ingredient product, Fexofast contains only Fexofenadine hydrochloride and does not contain a decongestant. Medications containing a decongestant alongside fexofenadine are separate combination products, which are typically used to treat nasal congestion.

Q: Are there any warnings regarding Fexofast and pre-existing medical conditions like glaucoma?

A: Warnings regarding conditions like glaucoma are generally associated with allergy medicines that contain a decongestant ingredient. Single-ingredient Fexofast is typically not contraindicated for glaucoma, but consulting a health professional is advised if you have any pre-existing medical conditions.

Q: What does the research say about Fexofast's effect on sleep quality?

A: While Fexofast is classified as non-sedating, post-marketing surveillance reports submitted to regulatory bodies have listed sleep-related adverse events, such as insomnia and other sleep disorders. These events have been reported with a frequency that is officially classified as 'not known.'

Q: Is Fexofast suitable for treating seasonal allergy symptoms only?

A: No, Fexofast is not indicated for seasonal allergy symptoms only. Regulatory documents confirm the medicine is approved for the relief of symptoms associated with Seasonal Allergic Rhinitis (hay fever) as well as the treatment of the skin manifestations of Chronic Idiopathic Urticaria (chronic hives).

Q: Why is it important to check the official product label before taking Fexofast?

A: Official product labels are legally required to contain critical information that ensures the medicine is used safely and effectively. This information includes approved uses, mandatory dosing instructions, warnings, side effects, and known drug interactions. Checking the official label ensures the user has the most current and authoritative guidance.

Q: Can Fexofast be used alongside a nasal spray for allergy relief?

A: General guidance from official health services suggests that it is generally acceptable to use Fexofast alongside certain other hay fever treatments, such as steroid nasal sprays. However, it is recommended that co-use be reviewed by a health professional.

Q: Is Fexofast commonly used for symptoms of the common cold or flu?

A: Fexofast is officially indicated only for the relief of symptoms that are caused by allergic reactions, such as those related to allergic rhinitis or chronic hives. It is not indicated for treating symptoms caused by the common cold or flu viruses.

Q: What are the official approved uses (indications) for Fexofast?

A: Official regulatory documents list two primary approved uses (indications) for Fexofast. These are the relief of symptoms associated with Seasonal Allergic Rhinitis (hay fever) and the treatment of skin manifestations of Chronic Idiopathic Urticaria (chronic hives).

Q: What should I do if I experience a rare but serious side effect from Fexofast?

A: Official safety information lists serious but rare adverse reactions, including systemic anaphylaxis (a severe allergic reaction), angioedema (swelling), and dyspnea (shortness of breath). Should a person experience any of these serious reactions, regulatory documents indicate that immediate professional medical attention is required.

Q: Is it OK to take Fexofast every day, even when I don't have allergy symptoms?

A: Fexofast is approved for use either episodically (as needed during symptomatic periods) or continuously for chronic conditions. Official guidance recommends discussing this specific pattern of use with a healthcare provider.

Q: Are there any official restrictions on who is eligible to use Fexofast?

A: Official documents define several eligibility restrictions for Fexofast. These include a contraindication for known hypersensitivity to the ingredients and an age limitation, as the drug is not recommended for children under six months. Additionally, caution and possible dose restrictions are advised for older adults and patients with decreased kidney function.

Q: Are there any specific warnings about using Fexofast if I have heart conditions?

A: Post-marketing reports reviewed by regulatory bodies have listed rare side effects such as tachycardia (fast heartbeat) and palpitations. However, specific warnings or contraindications for single-ingredient Fexofast regarding pre-existing severe heart conditions are primarily associated with combination products containing decongestants.

Q: How is Fexofast described in official documents regarding its use in children?

A: Official documents describe Fexofast use in children with specific, age-appropriate dosing schedules and formulations, such as oral suspension for younger patients. The medicine is approved for specific indications for children starting from six months of age, with guidelines detailing how the dose is determined based on age or weight.

Q: What is the relationship between Fexofast and histamines in the body?

A: Fexofast is chemically a selective peripheral H1-receptor antagonist. Its role is to bind to the H1-receptors in the body, which effectively blocks the action of histamine, the natural substance responsible for triggering allergic symptoms. This mechanism prevents the body's allergic response.

How should Fexofast be stored and disposed of?

How to Store and Dispose of Fexofast

Fexofast (fexofenadine hydrochloride) must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F), with permitted temperature excursions between 15°C and 30°C. The medication must be kept out of the sight and reach of children.

Storage and Handling

  • Protection: The product must be protected from excessive moisture and kept away from direct light.
  • Prohibited Environment: Fexofast must be kept from freezing and should not be used if the original packaging or safety seals are compromised.

Disposal Requirements

Do not dispose of unused or expired Fexofast by throwing it in household waste or flushing it down the toilet. You must ask a pharmacist or healthcare professional for guidance on proper disposal, such as utilizing official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fexofast found in:

A-Z Index: